Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:162
Name cancer
Definition A disease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
AKT1 wild-type Uprosertib cancer sensitive detail...
RET mutant Sorafenib cancer sensitive detail...
JAK2 Y931C Ruxolitinib cancer resistant detail...
JAK2 V617F JAK2 Y931C Ruxolitinib cancer resistant detail...
AKT1 E17K Uprosertib cancer sensitive detail...
HRAS wild-type FTI-277 cancer predicted - sensitive detail...
ETV6 - NTRK3 Midostaurin cancer sensitive detail...
JAK2 R683G JAK2 E864K NVP-BSK805 cancer resistant detail...
JAK2 R683G JAK2 E864K NVP-BVB808 cancer resistant detail...
JAK2 R683G JAK2 G935R Ruxolitinib cancer resistant detail...
JAK2 R683G JAK2 G935R NVP-BSK805 cancer resistant detail...
JAK2 R683G JAK2 G935R NVP-BVB808 cancer resistant detail...
RSPO3 over exp N/A cancer not applicable detail...
FLT3 I836del Tandutinib cancer sensitive detail...
FLT3 I836del Midostaurin cancer sensitive detail...
ERBB2 R188C Poziotinib cancer sensitive detail...
ERBB2 P489L Poziotinib cancer sensitive detail...
ERBB2 L1157R Poziotinib cancer sensitive detail...
ERBB2 L1157R Neratinib cancer sensitive detail...
ERBB2 R188C Neratinib cancer sensitive detail...
ERBB2 P489L Neratinib cancer sensitive detail...
ERBB2 R188C Afatinib cancer sensitive detail...
ERBB2 P489L Afatinib cancer sensitive detail...
ERBB2 L1157R Afatinib cancer sensitive detail...
ERBB2 L1157R Gefitinib cancer no benefit detail...
ERBB2 P489L Gefitinib cancer no benefit detail...
ERBB2 R188C Gefitinib cancer no benefit detail...
ERBB2 R188C Erlotinib cancer no benefit detail...
ERBB2 P489L Erlotinib cancer no benefit detail...
ERBB2 L1157R Erlotinib cancer no benefit detail...
ERBB2 L1157R Pelitinib cancer sensitive detail...
ERBB2 R188C Pelitinib cancer sensitive detail...
ERBB2 P489L Pelitinib cancer sensitive detail...
ERBB2 P489L Canertinib cancer sensitive detail...
ERBB2 L1157R Canertinib cancer sensitive detail...
ERBB2 R188C Canertinib cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02484053 Phase I Rituximab Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders Completed
NCT03543358 Phase II Rovalpituzumab Tesirine A Long-Term Study of Rovalpituzumab Tesirine Completed
NCT03768063 FDA approved Atezolizumab A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) Recruiting
NCT03844048 Phase III Venetoclax An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Enrolling by invitation
NCT03899155 FDA approved Nivolumab Pan Tumor Nivolumab Rollover Study Recruiting
NCT03912831 Phase I Cyclophosphamide + Fludarabine KITE-439 Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers Recruiting
NCT03926143 Phase II Anetumab ravtansine A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies Enrolling by invitation
NCT04464226 Phase III Darolutamide Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer Not yet recruiting